Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Aeglea Bio Therapeutics Inc    AGLE

AEGLEA BIO THERAPEUTICS INC (AGLE)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/18/2018 04/19/2018 04/20/2018 04/23/2018 04/24/2018 Date
8.49(c) 7.88(c) 7.87(c) 7.9(c) 8.28 Last
415 886 1 435 594 293 103 178 129 1 371 556 Volume
-9.87% -7.18% -0.13% +0.38% +4.81% Change
More quotes
Financials (USD)
Sales 2018 3,29 M
EBIT 2018 -30,4 M
Net income 2018 -30,0 M
Finance 2018 37,1 M
Yield 2018 -
Sales 2019 1,92 M
EBIT 2019 -41,3 M
Net income 2019 -44,0 M
Finance 2019 148 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 28,9x
EV / Sales2019 -8,15x
Capitalization 132 M
More Financials
Company
Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer.It develops pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1... 
More about the company
Surperformance© ratings of Aeglea Bio Therapeutics In
Trading Rating : Investor Rating :
More Ratings
Latest news on AEGLEA BIO THERAPEUTICS IN
04/19AEGLEA BIOTHERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other..
AQ
04/19AEGLEA BIO THERAPEUTICS : BioTherapeutics Prices Public Offering of Common Stock
AQ
04/18AEGLEA BIO THERAPEUTICS : BioTherapeutics Announces Proposed Public Offering of ..
AQ
04/17AEGLEA BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition (fo..
AQ
04/17Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
GL
04/16AEGLEA BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers, Financ..
AQ
04/16AEGLEA BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements an..
AQ
04/12Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinic..
GL
04/12AEGLEA BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements an..
AQ
04/05Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data..
GL
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/24On The Fly: Top five analyst initiations $FDC $AGN $ALDR $CVON $AGLE
2
04/24UPSIDE MOMENTUM ALERT: $AGLE AEGLEA BIOTHERAPEUTICS ? TradeIdeas via
1
04/24$AGLE (+7.6% pre) Aeglea BioTherapeutics, Inc. (AGLE): New Bullish Coverage ..
1
04/24Aeglea Bio Therapeutics started at outperform with $37 stock price target at .. 
04/21Zacks: Aeglea Bio Therapeutics Inc $AGLE Given $18.00 Consensus Price Target .. 
More tweets
Qtime:118
News from SeekingAlpha
04/24PREMARKET GAINERS AS OF 9 : 05 am (04/24/2018) 
04/24Premarket analyst action - healthcare 
04/19HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (04/19/2018) 
04/19PREMARKET LOSERS AS OF 9 : 05 am (04/19/2018) 
04/19Aeglea prices stock offering at $8 
Chart AEGLEA BIO THERAPEUTICS IN
Duration : Period :
Aeglea Bio Therapeutics In Technical Analysis Chart | AGLE | US00773J1034 | 4-Traders
Technical analysis trends AEGLEA BIO THERAPEUTICS IN
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 17,5 $
Spread / Average Target 122%
EPS Revisions
Managers
NameTitle
Anthony G. Quinn Chief Executive Officer & Director
Armen B. Shanafelt Chairman
Charles N. York Chief Financial Officer & Vice President
James Wooldridge Chief Medical Officer
George Georgiou Director
Sector and Competitors
1st jan.Capitalization (M$)
AEGLEA BIO THERAPEUTICS INC46.03%132
GILEAD SCIENCES2.88%96 094
VERTEX PHARMACEUTICALS5.53%40 153
REGENERON PHARMACEUTICALS-16.41%33 844
GENMAB23.13%12 797
BEIGENE LTD (ADR)73.60%8 998